ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

03 Mar 2021

ISA106’s promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-19 therapy

March 3rd, 2021 – ISA announces that it has completed pre-clinical work for ISA106, a novel COVID-19 immunotherapy and is planning clinical trials. A phase 1 dose finding study in healthy volunteers will start in the next few months.

ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU. It is designed to elicit a robust T cell immune response specifically against SARS-CoV2,

Read more »

ISA106 – SLP therapeutic for COVID-19

11 Jan 2021

Interview with ISA Pharmaceuticals’ CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cell immune response against SARS-CoV2.

Winter can be the worst time for respiratory diseases. As the nights draw in and we huddle together against the cold and dark, sneezing and wheezing, we spread our coughs, colds, and worse. Many people can find breathing a struggle in a normal winter, and this year there is the COVID-19 virus stalking the land, seeking lungs to infiltrate, causing the terrible pandemic that we are all caught up in. Whilst the news is, finally, full

Read more »